Ricardo G. Teixeira

Mr. Ricardo G. Teixeira

Faculdade de Ciências da Universidade de Lisboa, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2018 in Inorganic Chemistry
Verified
Journal Article
Closed access
Leonor Côrte-RealLeonor Côrte-Real
Leonor Côrte-Real
RTRicardo G. Teixeira
Ricardo G. Teixeira
PGPatrícia Gírio
Patrícia Gírio
ECElisabeta COMSA
Elisabeta COMSA
AMAlexis MORENO
Alexis MORENO
Andreia ValenteAndreia Valente
Andreia Valente

17 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CTCatarina Teixeira
Catarina Teixeira
ABAna Rita Brás
Ana Rita Brás
RTRicardo G. Teixeira
Ricardo G. Teixeira
Andreia ValenteAndreia Valente
Andreia Valente
Ana PretoAna Preto
Ana Preto
Colorectal cancer (CRC) is one of the most common malignancies and one of the leading causes of cancer-related death worldwide, urging the need for new and more efficient therapeutic approaches. Ruthenium complexes have emerged as attractive alternatives to traditional platinum-based compounds in the treatment of CRC. This work aims to evaluate anti-CRC properties, as well as to identify the mechanisms of action of ruthenium complexes with the general formula [Ru(η5-C5H4R)(PPh3)(4,4′-R′-2,2′-bipyridine)][CF3SO3], where R = CH3, CHO or CH2OH and R′ = H, CH3, CH2OH, or dibiotin ester. The complexes (Ru 1–7) displayed high bioactivity, as shown by low IC50 concentrations against CRC cells, namely, RKO and SW480. Four of the most promising ruthenium complexes (Ru 2, 5–7) were phenotypically characterized and were shown to inhibit cell viability by decreasing cell proliferation, inducing cell cycle arrest, and increasing apoptosis. These findings were in accordance with the inhibition of MEK/ERK and PI3K/AKT signaling pathways. Ruthenium complexes also led to a decrease in cellular clonogenic ability and cell migration, which was associated with the disruption of F-actin cytoskeleton integrity. Here, we demonstrated that ruthenium complexes, especially Ru7, have a high anticancer effect against CRC cells and are promising drugs to be used as a new therapeutical strategy for CRC treatment.

1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RTRicardo G. Teixeira
Ricardo G. Teixeira
ABAna Rita Brás
Ana Rita Brás
Leonor Côrte-RealLeonor Côrte-Real
Leonor Côrte-Real
RTRajendhraprasad Tatikonda
Rajendhraprasad Tatikonda
ASAnabela Sanches
Anabela Sanches
Andreia ValenteAndreia Valente
Andreia Valente

23 April 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
RTRicardo G. Teixeira
Ricardo G. Teixeira
FMFernanda Marques
Fernanda Marques
MRMaria Paula Robalo
Maria Paula Robalo
XFXavier Fontrodona
Xavier Fontrodona
MGM. Helena Garcia
M. Helena Garcia
Andreia ValenteAndreia Valente
Andreia Valente
Ruthenium complexes of carboranyl ligands offer the possibility of dual action (chemo + radiotherapy) that might result in significant clinical benefits. In that frame, we describe herein the development of ruthenium–carboranyl complexes bearing bipyridyl derivatives with the general formula [3-CO-3,3-{κ2-4,4′-R2-2,2′-bipy}-closo-3,1,2-RuC2B9H11] (R = CH3, RuCB1 or R = CH2OH, RuCB2). Both compounds crystallized in the monoclinic system, showing the expected three-legged piano stool structure. The ruthenacarboranes are stable in cell culture media and were tested against two cell lines that have shown favorable clinical responses with BNCT, namely melanoma (A375) and glioblastoma (U87). RuCB1 shows no cytotoxic activity up to 100 μM while RuCB2 showed moderate activity for both cell lines. Cell distribution assays showed that RuCB2 presents high boron internalization that is proportional to the concentration used indicating that RuCB2 presents features to be further studied as a potential anticancer bimodal agent (chemo + radiotherapy).

31 October 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RTRicardo G. Teixeira
Ricardo G. Teixeira
JMJános P. Mészáros
János P. Mészáros
BMBeatriz Matos
Beatriz Matos
LCLeonor Côrte-Real
Leonor Côrte-Real
Cristina P R XavierCristina P R Xavier
Cristina P R Xavier
Andreia ValenteAndreia Valente
Andreia Valente
A family of ten novel ruthenium(II)-cyclopentadienyl organometallics of general formula [Ru(η5-C5H5)(N,N)(PPh2(C6H4COOR)][CF3SO3] (1-10) in which (N,N) = 4,4'-R'-2,2'-bipyridyl (R = -H or -CH2CH2OH; R' = -H, -CH3, -OCH3, -CH2OH, and -CH2-biotin) was prepared from [Ru(η5-C5H5)(PPh2(C6H4COOH))2Cl]. All compounds were fully characterized by means of several spectroscopic and analytical techniques, and the molecular structures of [Ru(η5-C5H5)(PPh2(C6H4COOH))2Cl], 1, 3 and 4 have been additionally studied by single-crystal X-ray diffraction. The anticancer activity of all compounds was evaluated in sensitive and multidrug-resistant counterpart cell lines from human colorectal cancer (Colo 205 and Colo 320) and non-small cell lung cancer NSCLC (A549, NCI-H460 versus NCI-H460/R) as well. Notably, compounds 6 and 7 (R CH2CH2OH and (N,N) = bipy or Me2bipy, respectively) showed antiproliferative effect against both cell lines with high intrinsic selectivity towards cancer cells. The antibacterial activity of all compounds was also evaluated against both Gram negative and Gram positive strains, and some compounds in the series showed potent antibacterial activity against Staphylococcus aureus strains, including the methicillin-resistant MRSA strains. Solution speciation studies revealed that the complexes bearing the PPh2(C6H4COO-) ligand are neutral at physiological pH (7.4) in contrast with their ethylene glycol derivatives that have a permanent positive charge. While all compounds are lipophilic, the difference in the distribution coefficient for neutral and charged complexes is around one order of magnitude. Complexes 6 and 7 exhibited excellent biological activity and were selected for further studies. Spectrofluorometric methods were used to investigate their interaction with biomolecules such as human serum albumin (HSA) and calf thymus DNA (ct-DNA). For these complexes, binding site II of HSA is a possible binding pocket through non-covalent interactions. The release of ethidium from the DNA adduct by the charged complexes proves their interaction with DNA in contrast to the neutral ones. In conclusion, Ru(II)-cyclopentadienyl complexes with 2,2'-bipyridyl-derivatives and an ethylene glycol moiety tethered to the phenylphosphane co-ligand are very promising from a therapeutic perspective, in particular complexes 6 and 7 that display remarkable antibacterial activity with a high anti-proliferative effect against colon and non-small cell lung cancers, both clinically challenging neoplasias in need of effective solutions.

13 January 2026 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
RTRicardo G. Teixeira
Ricardo G. Teixeira
LSLívia Stenico
Lívia Stenico
XFXavier Fontrodona
Xavier Fontrodona
IRIsabel Romero
Isabel Romero
Radoslaw StarostaRadoslaw Starosta
Radoslaw Starosta
Andreia ValenteAndreia Valente
Andreia Valente
Novel fluorescent Ru( ii )–Cp complexes exhibit strong anticancer activity, particularly against U2OS cells. They enter cells via caveolin-mediated endocytosis, accumulate in lysosomes, and induce oxidative stress–driven apoptosis.